“SpikoGen®”, a joint venture between Vaxine and CinnaGen

In a new cooperation agreement, Phases 2 and 3 clinical trials of the Vaxine’s monovalent recombinant COVID-19 vaccine will be initiated in Iran in the coming weeks. If these studies are successful, this Australian vaccine will be produced under the brand name “SpikoGen®” by CinnaGen Company and will be rolled out in Iran.